CD32-mediated platelet aggregation in vitro by antithymocyte globulin: Implication of therapy-induced in vivo thrombocytopenia

American Journal of Transplantation

Volumn 3, Issue 6, 2003, Pages 754-759

  Ankersmit, Hendrik Jan ^a   Roth, Georg Alexander ^a   Moser, Bernhard ^a   Zuckermann, Andreas ^a   Brunner, Markus ^a   Rosin, Christiane ^a   Buchta, Christoph ^a   Bielek, Edith ^a   Schmid, Werner ^a   Jensen Jarolim, Erika ^a   Wolner, Ernst ^a   Boltz Nitulescu, George ^a   Volf, Ivo ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

Antibodies; Antilymphocyte induction therapy; Monoclonal antibodies; Thrombocytopenia

Indexed keywords

AZATHIOPRINE; CD32 ANTIGEN; CD40 LIGAND; CD63 ANTIGEN; CYCLOSPORIN A; FC RECEPTOR; INTERLEUKIN 2 RECEPTOR ANTIBODY; OKT 3; PADGEM PROTEIN; STEROID; THYMOCYTE ANTIBODY;

ADULT; ANTIGEN EXPRESSION; ARTICLE; CELL STRUCTURE; CONTROLLED STUDY; DRUG INDUCED DISEASE; ELECTRON MICROSCOPY; FLOW CYTOMETRY; GRAFT REJECTION; HEART TRANSPLANTATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; THROMBOCYTE AGGREGATION; THROMBOCYTOPENIA;

FLOW CYTOMETRY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PLATELET AGGREGATION; RECEPTORS, IGG; THROMBOCYTOPENIA; THYMUS GLAND;

EID: 0037531569     PISSN: 16006135     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-6143.2003.00150.x     Document Type: Article

References (27)

1. Cosimi AB. Antilymphocyte globulins and monoclonal antibodies. In: Morris PJ, eds. Kidney Transplantation: Principle and Practice. Philadelphia: WB Saunders; 1988. p. 343.
2. de Planque MM, Bacigalupo A, Wursch A et al. Long-term follow-up of severe aplastic anaemia patients treated with antithymocyte globulin. Severe Aplastic Anaemia Working Party of the European Cooperative Group for Bone Marrow Transplantation (EBMT). Br J Haematol 1989; 73: 121-126.
3. Ankersmit HJ, Moser B, Zuckermann A et al. Activation-induced T cell death, and aberrant T cell activation via TNFR1 and CD95-CD95L ligand pathway in stable cardiac transplant recipients. Clin Exp Immunol 2002; 128: 175-180.
4. Zuckermann AO, Grimm M, Czerny M et al. Improved long term results with thymoglobuline induction therapy after cardiac transplantation: a comparison of two different rabbit-antithymocyte globulines. Transplantation 2000; 69: 1890-1898.
5. Debure A, Chkoff N, Chatenoud L et al. One-month prophylactic use of OKT3 in cadaver kidney transplant recipients. Transplantation 1988; 45: 546-553.
6. Bock HA, Gallati H, Zurcher RM et al. A randomized prospective trial of prophylactic immunosuppression with ATG-fresenius versus OKT3 after renal transplantation. Transplantation 1995; 59: 830-840.
7. Beniaminovitz A, Itescu S, Lietz K et al. Prevention of rejection in cardiac transplantation by blockade of the interleukin-2 receptor with a monoclonal antibody. N Engl J Med 2000; 342: 613-619.
8. Rebellato LM, Gross U, Verbanac KM, Thomas JM. A comprehensive definition of the major antibody specificities in polyclonal rabbit antithymocyte globulin. Transplantation 1994; 57: 685-694.
9. Bonnefoy-Berard N, Vincent C, Revillard JP. Antibodies against functional leukocyte surface molecules in polyclonal antilymphocyte and antithymocyte globulins. Transplantation 1991; 51: 669-673.
10. Preville X, Nicolas L, Flacher M, Revillard JP. A quantitative flow cytometry assay for the preclinical testing and pharmacological monitoring of rabbit antilymphocyte globulines (rATG). J Immunol Meth 2000; 245: 45-54.
11. Greco B, Bielory L, Stephany D et al. Antithymocyte globulin reacts with many normal human cell types. Blood 1983; 62: 1047-1054.
12. Raefsky EL, Gascon P, Gratwohl A, Speck B, Young NS. Biological and immunological characterization of ATG and ALG. Blood 1986; 68: 712-719.
13. Condie RM, White JG, Najarian JS. Platelet activity of antilymphocyte (ALS) preparations. Transplant Proc 1973; 5: 555-559.
14. Najarian JS, Simmons RL, Condie RM et al. Seven years' experience with antilymphoblast globulin for renal transplantation from cadaver donors. Ann Surg 1976; 184: 352-368.
15. Novick AC, Braun WE, Steinmuller D, Buszta C, Greenstreet R, Kiser W. A controlled randomised double-blind study of anti-lymphoblast globulin in cadaver renal transplantation. Transplantation 1983; 35: 175-179.
16. Madaio MP, Spiegel JE, Levey AS. Life-threatening thrombocytopenia complicating antithymocyte globulin therapy for acute kidney transplant rejection. Evidence of in situ immune complex formation on the platelet surface. Transplantation 1988; 45: 647-649.
17. Bachelot C, Saffroy R, Gandrille S, Aiach M, Rendu F. Role of FcγRIIA gene polymorphism in human platelet activation by monoclonal antibodies. Thromb Haemost 1995; 74: 1557-1563.
18. Viallard JF, Solanilla A, Gauthier B et al. Increased soluble and platelet-associated CD40 ligand in essential thrombocythemia and reactive thrombocytosis. Blood 2002; 99: 2612-2614.
19. Rubinstein E, Kouns WC, Jennings LK, Boucheix C, Carroll RC, Interaction of two GPIIb/IIIa monoclonal antibodies with platelet Fc receptor (Fc gamma RII). Br J Haematol 1991; 78: 80-86.
20. Borne AE, Modderman PW, Admiraal LG, Nieuwenhuis HK, Platelet antibodies, the overall results. In: Leukocyte Typing IV. Oxford: Oxford University Press; 1989. p. 951.
21. Pidard D, Montgomery RR, Bennet JS, Kunicki TJ. Interaction of AP-2, a monoclonal antibody specific for human platelet glycoprotein IIb-IIIa complex, with intact platelets. J Biol Chem 1983; 258: 12582-12586.
22. Bennett JS, Hoxie JA, Leitmann SF, Vilaire G, Clines DB. Inhibition of fibrinogen binding to stimulated platelets by a monoclonal antibody. Proc Natl Acad Sci USA 1983; 80: 2417-2421.
23. Jennings LK, Phillips DR, Walker WS. Monoclonal antibodies to human platelet glycoprotein IIb beta that initiate distinct platelet responses. Blood 1985; 65: 1112-1119.
24. Gulino D, Ryckewaert JJ, Andrieux A, Rabiet MJ, Marguerie G. Identification of a monoclonal antibody against platelet GPIIb that interacts with a calcium-binding site and induces aggregation. J Biol Chem 1990; 265: 9575-9581.
25. Worthington RE, Carroll RC, Boucheix C. Platelet activation by CD9 monoclonal antibodies is mediated by the Fc gamma II receptor. Br J Haematol 1990; 74: 216-222.
26. McKenzie SE, Taylor SM, Malladi P et al. The role of the human FcγRIIA in the immune clearance of platelets: a transgenic mouse model. J Immunol 1999; 162: 4311-4318.
27. Henn V, Steinbach S, Büchner K, Presek P, Krocek R. The inflammatory action of CD40L (CD154) expressed on activated human platelets is temporally limited by coexpressed CD40. Blood 2001; 98: 1047-1054.